Table 1.
Description of the 401 women included in the study
| Total | CLART | LA | HC2 | P | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| High-risk genotypes | Low-risk genotypes | No HPV genotypesc | High-risk genotypes | Low-risk genotypes | No HPV genotypesc | Positive test result | Negative test result | CLART vs. LA | CLART vs. HC2 | ||
| Total | 401 (100%) | 311 (78%) | 54 (13%) | 36 (9%) | 326 (81%) | 54 (13%) | 21 (5%) | 355 (89%) | 46 (11%) | ||
| Age (years) | |||||||||||
| <30 | 215 (100%) | 180 (84%) | 21 (10%) | 14 (7%) | 184 (86%) | 21 (10%) | 10 (5%) | 192 (89%) | 23 (11%) | 0.701 | 0.090 |
| 30-39 | 96 (100%) | 74 (77%) | 16 (17%) | 6 (6%) | 80 (83%) | 13 (14%) | 3 (3%) | 86 (90%) | 10 (10%) | 0.462 | 0.020 |
| ≥40 | 90 (100%) | 57 (63%) | 17 (19%) | 16 (18%) | 62 (69%) | 20 (22%) | 8 (9%) | 77 (86%) | 13 (14%) | 0.210 | 0.001 |
| P | 0.001 | 0.012 | 0.602 | ||||||||
| Cytology | |||||||||||
| ASCUS | 103 (100%) | 78 (76%) | 11 (11%) | 14 (14%) | 82 (80%) | 10 (10%) | 11 (11%) | 88 (85%) | 15 (15%) | 0.776 | 0.078 |
| LSIL | 161 (100%) | 113 (70%) | 37 (23%) | 11 (7%) | 119 (74%) | 38 (24%) | 4 (2%) | 140 (87%) | 21 (13%) | 0.180 | <0.001 |
| ≥HSILa | 137 (100%) | 120 (88%) | 6 (4%) | 11 (8%) | 125 (91%) | 6 (4%) | 6 (4%) | 127 (93%) | 10 (7%) | 0.455 | 0.156 |
| P | <0.001 | <0.001 | 0.156 | ||||||||
| Worst follow-up outcome | |||||||||||
| No follow-up | 17 (100%) | 14 (82%) | 2 (12%) | 1 (6%) | 14 (82%) | 3 (18%) | 0 (0%) | 16 (94%) | 1 (6%) | 0.549 | 0.287 |
| Normal cytology or negative HPV test | 75 (100%) | 56 (75%) | 8 (11%) | 11 (15%) | 60 (80%) | 6 (8%) | 9 (12%) | 60 (80%) | 15 (20%) | 0.732 | 0.435 |
| Abnormal cytology or positive HPV test | 10 (100%) | 7 (70%) | 2 (20%) | 1 (10%) | 8 (80%) | 2 (20%) | 0 (0%) | 8 (80%) | 2 (20%) | 0.587 | 0.605 |
| Inadequate histology | 9 (100%) | 3 (33%) | 3 (33%) | 3 (33%) | 3 (33%) | 3 (33%) | 3 (33%) | 6 (67%) | 3 (33%) | 1.000 | 0.157 |
| CIN0 | 98 (100%) | 57 (58%) | 29 (30%) | 12 (12%) | 61 (62%) | 31 (32%) | 6 (6%) | 77 (79%) | 21 (21%) | 0.333 | 0.002 |
| CIN1b | 67 (100%) | 58 (87%) | 5 (7%) | 4 (6%) | 60 (90%) | 5 (7%) | 2 (3%) | 65 (97%) | 2 (3%) | 0.704 | 0.028 |
| CIN2 | 35 (100%) | 32 (91%) | 2 (6%) | 1 (3%) | 33 (94%) | 2 (6%) | 0 (0%) | 34 (97%) | 1 (3%) | 0.602 | 0.303 |
| CIN3 | 86 (100%) | 81 (94%) | 3 (3%) | 2 (2%) | 83 (97%) | 2 (2%) | 1 (1%) | 85 (99%) | 1 (1%) | 0.757 | 0.096 |
| Cervical cancer | 4 (100%) | 3 (75%) | 0 (0%) | 1 (25%) | 4 (100%) | 0 (0%) | 0 (0%) | 4 (100%) | 0 (0%) | 0.285 | 0.285 |
| P | <0.001 | <0.001 | <0.001 | ||||||||
Abbreviations:ASCUS atypical squamous cells of undetermined significance, CIN cervical intraepithelial neoplasia, HPV human papillomavirus, HSIL high-grade squamous intraepithelial lesions, LSIL low-grade squamous intraepithelial lesions.
aIncluding atypical squamous cells – cannot exclude HSIL, adenocarcinoma in situ, atypical glandular cells, cytological signs of carcinoma.
bIncluding histological atypia and CIN not otherwise specified.
cOr HPV genotypes not detectable by both CLART and LA (CLART: 43, 44, 85, 89; LA: 55, 64, 67, 69, IS39, CP6108).